Ixekizumab: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Myanmar prescribing information.

Generic Medicine Info

Indications and Dosage

Subcutaneous
Plaque psoriasis

Adult: Initially, 160 mg once, then followed by 80 mg once every 2 weeks for 6 doses (at weeks 2, 4, 6, 8, 10 and 12). Maintenance: 80 mg every 4 weeks. Consider treatment discontinuation if there is no response after 16-20 weeks.

Subcutaneous
Psoriatic arthritis

Adult: Patient who are intolerant to previous disease-modifying antirheumatic drugs (DMARDs) therapy: As monotherapy or in combination with a DMARD (e.g. methotrexate): Initially, 160 mg once, then followed by 80 mg every 4 weeks. Consider treatment discontinuation if there is no response after 16-20 weeks. Patient with concomitant moderate to severe plaque psoriasis, follow dosing guidelines for plaque psoriasis.

Contraindications

Hypersensitivity. Active infection (e.g. TB). Pregnancy. Administration of live vaccine.

Special Precautions

Patients with chronic or recurrent infection and inflammatory bowel disease (e.g. Crohn’s disease, ulcerative colitis). Lactation.

Adverse Reactions

Significant: Hypersensitivity reactions (e.g. urticaria, angioedema, anaphylaxis), infections (e.g. upper respiratory tract infection, oral candidiasis, conjunctivitis, tinea infections).
Blood and lymphatic system disorders: Neutropenia, thrombocytopenia.
Gastrointestinal disorders: Nausea.
General disorders and administration site conditions: Inj site reactions (e.g. erythema, pain).
Infections and infestations: Herpes simplex (mucocutaneous), influenza, cellulitis.
Respiratory, thoracic and mediastinal disorders: Oropharyngeal pain, upper respiratory tract infection, rhinitis.
Skin and subcutaneous tissue disorders: Rash, urticaria, eczema.

Monitoring Parameters

Monitor for hypersensitivity reactions, signs and symptoms of infection, active TB (during and after treatment) and inflammatory bowel disease.

Drug Interactions

Potentially Fatal: May enhance the adverse effects and diminish the therapeutic effect of live vaccines.

Action

Description: Ixekizumab is a humanised immunoglobulin G₄ (IgG₄ kappa) monoclonal antibody that selectively binds with the interleukin 17A (IL-17A), a cytokine involved in normal inflammatory and immune responses, thus inhibiting the release of proinflammatory cytokines and chemokines.
Pharmacokinetics:
Absorption: Bioavailability: 60-81%. Time to peak plasma concentration: Approx 4 days.
Distribution: Crosses placenta. Volume of distribution steady-state: 7.1 L.
Metabolism: Expected to be degraded into small peptides and amino acids via catabolic pathways.
Excretion: Elimination half-life: 13 days.

Storage

Store between 2-8°C or below 30°C for up to 5 days. Do not freeze. Protect from light. Any unused portion should be disposed of in accordance with local requirements.

MIMS Class

Psoriasis, Seborrhea & Ichthyosis Preparations

ATC Classification

L04AC13 - ixekizumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.

References

Anon. Ixekizumab. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 07/08/2019.

Anon. Ixekizumab. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 07/08/2019.

Buckingham R (ed). Ixekizumab. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/08/2019.

Joint Formulary Committee. Ixekizumab. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/08/2019.

Taltz Injection Solution (Eli Lilly and Company). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 07/08/2019.

Disclaimer: This information is independently developed by MIMS based on Ixekizumab from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com